As the cancer day care centre at AIIMS, Delhi, spills over, families hope decentralised treatment will cut costs, minimise ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

Panjim: The Goa Health Department, alongside AstraZeneca and Qure.ai, is launching multiple initiatives to improve cancer ...

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

Deemed as the “drug that changed the breast cancer treatment landscape,” Herceptin has saved millions of women's lives ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.